Previous studies have shown that anlotinib plus third‐generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) overcome acquired resistance to EGFR‐TKIs in patients with advanced EGFR‐mutant nonsmall cell lung cancer (NSCLC). Here, EGF is linked to non-small cell lung carcinoma.